Kintor Pharma announced that its topical androgen receptor antagonist pyrilutamide hit its Phase 3 primary endpoint in a 666-patient hair loss trial in China. The data is encouraging on paper, but readers should keep several caveats in mind: these are top-line company-reported results, the trial was conducted entirely in China, and Kintor has been a recurring point of debate in the hair loss community.
KX-826, also known as pyrilutamide, is a topical androgen receptor (AR) antagonist developed by Kintor Pharmaceutical (HKEX: 9939). It is designed to block androgen-mediated signaling directly at the hair follicle by competing with androgens like DHT for binding to the androgen receptor in local tissue.
Unlike oral finasteride or dutasteride, which reduce systemic DHT levels, pyrilutamide is designed to work locally at the scalp. It has very low transdermal absorption and its metabolites are low-activity compounds, which in theory may reduce the risk of systemic adverse effects relative to oral anti-androgens. However, longer and broader datasets will be needed to confirm this.
In preclinical binding affinity data, pyrilutamide appears to be the most potent of the topical AR antagonists currently in development. One way to measure this is IC50, which is the concentration of drug needed to block 50% of the target's activity. A lower IC50 means the drug is more potent. Pyrilutamide has an IC50 of 0.28 nM, compared to roughly 50 nM for clascoterone (Breezula/Winlevi) and roughly 40 uM for fluridil. In practical terms, pyrilutamide is roughly 180 times more potent by this measure. RU58841 is also used in the community but has less formal data. These comparisons come from different assay systems and should be interpreted with some caution, but the difference in potency is large.
On March 18, 2026, Kintor announced that the Phase 3 stage of its pivotal clinical trial for KX-826 tincture 1.0% reached its primary endpoint with statistically significant and clinically meaningful outcomes. These are top-line, company-reported results; full data has not yet been published or peer-reviewed.
The trial was a multi-center, randomized, double-blind, vehicle-controlled Phase II/III study with an adaptive design conducted at 26 clinical research centers in China. It enrolled 666 male patients with androgenetic alopecia and ran for 24 weeks of treatment plus a 14-day safety observation period.
The primary endpoint was change in target area non-vellus hair count (TAHC) from baseline:
1.0% BID (twice daily): +15.33 hairs/cm² from baseline, which was +10.65 hairs/cm² over placebo (p<0.0001).
0.5% BID (twice daily): +14.46 hairs/cm² from baseline, which was +9.78 hairs/cm² over placebo (p<0.0001).
Placebo: +4.68 hairs/cm² from baseline.
Top-line data suggest a favorable safety profile: no drug-related serious adverse events were reported, and there were no clinically significant differences in adverse event rates between the treatment groups and placebo.
The placebo-adjusted gain of +10.65 hairs/cm² at 24 weeks is directionally encouraging and looks competitive with established therapies. However, cross-trial comparisons should be made cautiously: populations, endpoints, baseline severity, counting methods, and timepoints differ across studies. The result is a meaningful signal for a topical treatment, but we should wait for head-to-head data before drawing firm conclusions about relative efficacy.
The most relevant comparison is Cosmo Pharmaceuticals' clascoterone (marketed as Breezula), another topical AR antagonist. Cosmo reported positive Phase 3 topline data in December 2025 and said it was preparing for parallel U.S. and European submissions following completion of the full safety dataset. Both drugs target the same receptor, but pyrilutamide has significantly higher binding affinity in preclinical data.
Kintor explicitly referenced this in their press release, positioning KX-826 as a potential competitor to Breezula and stating their goal is to be the first-in-class drug approved globally for topical AR antagonist treatment of AGA.
This is one of the biggest asterisks on the KX-826 data. The Phase 3 trial enrolled 666 patients across 26 centers, all in China, with an all-Chinese patient population. The NDA filing is planned with Chinese drug regulatory authorities, with no mention of US or EU filing in the press release.
China-only data may not be enough on its own for broad Western regulatory confidence or clinician uptake, especially for a product expected to compete globally. Genetic background, hair characteristics, and regulatory standards differ across populations. This does not invalidate the Chinese data, but it does mean that pyrilutamide is likely still years away from being available outside of China through regulatory channels.
Kintor has a credibility problem. The company has been accused of presenting misleading clinical data, and multiple researchers in the hair loss community have flagged concerns about how Kintor interprets and markets its study results. The company has been largely unresponsive to engagement from independent researchers. These are community-level accusations, not regulatory findings, but they are widespread and consistent.
Kintor has also been selling a cosmetic version of KX-826 on Amazon, which has caused significant confusion. The cosmetic version lists 0.5% pyrilutamide, which is close to the concentration that performed well in the Phase 3 trial (the 0.5% BID arm showed +9.78 hairs/cm² over placebo, nearly matching the 1.0% arm). On paper, that might suggest the Amazon product should work similarly. But the clinical formulation was developed as a drug with a specific vehicle chemistry designed for follicular penetration, manufactured under pharmaceutical-grade quality controls. The Amazon version is classified as a cosmetic, uses kopexil instead of minoxidil in its base, and is held to different manufacturing standards. Vehicle matters enormously for topicals: the same active ingredient at the same concentration in a different base can have dramatically different local bioavailability. Community reports of the Amazon cosmetic version have been consistently disappointing, which underscores this distinction.
Despite widespread skepticism toward Kintor as a company, the hair loss community is broadly positive on pyrilutamide as a molecule. The binding affinity data is strong: the IC50 of 0.28 nM is dramatically better than clascoterone and fluridil. The Ki (inhibition constant, a measure of how tightly a drug binds to its target receptor) is 24 nM in competitive binding assays, which also looks promising. However, DHT is a "stickier" ligand (its own Ki for the androgen receptor is in the low single-digit nanomolar range), which means you need high local concentrations of the drug to actually outcompete DHT for receptor binding.
Anecdotally, some long-term self-experimenters report favorable tolerability and efficacy with pyrilutamide. One experienced user described it as the only AR receptor antagonist that gave no side effects while providing the best efficacy. Real-world protocols in the community typically combine pyrilutamide with topical or low-dose oral dutasteride as a complementary approach. These reports are not a substitute for controlled long-term trial data, but they do provide useful signal about real-world tolerability.
One concern that has been raised: potential efficacy degradation over time. Some users have reported a plateau in results around 6 months, which may be specific to pyrilutamide rather than a general AR antagonist issue. Longer-term data from controlled trials would help clarify this.
Kintor is also developing GT20029, a PROTAC-based androgen receptor degrader. Unlike pyrilutamide, which blocks the AR, GT20029 aims to remove the receptor entirely. The PROTAC mechanism is conceptually interesting, but Phase 2 data was underwhelming: it showed no clear dose-response relationship and only modest separation from placebo. Main theories for the underperformance include pharmacokinetic challenges and the molecule being too large to penetrate effectively.
Very low systemic exposure (cmax <0.003 ng/mL) is seen as a potential safety advantage, and one community member noted that GT20029 could theoretically allow use of exogenous androgens (like TRT) without hair loss, since the AR would not exist in follicles to be activated. Community timeline estimates for GT20029 are optimistic at around 4 years, but given the underwhelming Phase 2 data, many remain skeptical.
Kintor has stated they plan to communicate with Chinese drug regulatory authorities and initiate the NDA submission for KX-826 1.0% in the near term. If approved in China, it could be available there within 1 to 2 years.
For the US and EU, the timeline is much longer. There is no announced US Phase 3 trial yet. Even if one were to start in 2026, it would take 2 to 3 years to complete, followed by another 12 to 18 months for FDA review. A realistic estimate for US availability would be 2030 at the earliest, assuming everything goes smoothly.
Our take: if pyrilutamide works as the Phase 3 data suggests, the realistic expectation is moderate regrowth and meaningful stabilization, not a full reversal of advanced hair loss. The trial showed roughly 10-15 new non-vellus hairs per cm² over 24 weeks, which is a solid result but not transformative on its own.
Where pyrilutamide gets more interesting is as part of a combination protocol. Because it works by blocking androgens at the receptor rather than reducing DHT systemically or stimulating growth directly, it pairs naturally with treatments that work through different mechanisms: minoxidil (potassium channel opening), microneedling (wound-healing response), low-dose oral or topical dutasteride (DHT reduction), topical T3 (thyroid-mediated metabolism), and latanoprost (prostaglandin pathway).
If pyrilutamide eventually reaches Western markets, its real value will likely be as the anti-androgen layer in a broader protocol rather than as a standalone treatment. That combination potential is what makes this molecule worth watching.
We will be watching closely for any US Phase 3 trial announcements. If pyrilutamide can replicate these results in a Western patient population with FDA-grade oversight, it would be a significant addition to the hair loss treatment landscape.
It is too early to say. The Phase 3 placebo-adjusted hair count gains are in a broadly similar range to what finasteride achieves, but these are cross-trial comparisons with different populations, endpoints, and timepoints. No head-to-head trial has been conducted. The potential advantage of pyrilutamide is that it works topically at the receptor rather than reducing systemic DHT, which may mean fewer systemic side effects, but this has not been proven in long-term comparative studies.
In the Phase 3 trial, top-line data reported no drug-related serious adverse events and no clinically significant difference in adverse event rates between pyrilutamide and placebo. However, these are company-reported top-line results from a 24-week trial. Longer-term safety data across larger and more diverse populations will be important before drawing firm conclusions about the full side effect profile.
There is no announced US Phase 3 trial for pyrilutamide yet. Even if one were to begin in 2026, it would take 2 to 3 years to complete, plus 12 to 18 months for FDA review. A realistic estimate for US availability is 2030 at the earliest. Kintor is currently pursuing NDA filing in China only.
No. Kintor sells a cosmetic product containing 0.5% pyrilutamide on Amazon, but it is not the same as the clinical-grade formulation used in the Phase 3 trial. The Amazon version uses a different vehicle (kopexil instead of minoxidil), is manufactured under cosmetic rather than pharmaceutical standards, and has produced consistently disappointing results according to community reports. The vehicle chemistry matters enormously for topical drug delivery, so the same active ingredient in a different base can perform very differently.
Both are topical androgen receptor antagonists, but pyrilutamide has significantly higher binding affinity in preclinical data (IC50 of 0.28 nM vs roughly 50 nM for clascoterone). Cosmo Pharmaceuticals reported positive Phase 3 data for clascoterone in December 2025 and is preparing for US and EU regulatory submissions. Pyrilutamide does not yet have Western regulatory filings. A direct clinical comparison has not been conducted.
Kintor Pharmaceutical Limited. "Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint." Press release, March 18, 2026.
Cosmo Pharmaceuticals. Breezula (clascoterone) Phase 3 results announcement. December 2025.
ClinicalTrials.gov. Kintor Pharmaceutical KX-826 clinical trial listings.
Kintor Pharmaceutical Limited. Official press release. Kintor Pharma
Kintor Pharma announced that its topical androgen receptor antagonist pyrilutamide hit its Phase 3 primary endpoint in a 666-patient hair loss trial in China. The data is encouraging on paper, but readers should keep several caveats in mind: these are top-line company-reported results, the trial was conducted entirely in China, and Kintor has been a recurring point of debate in the hair loss community.
KX-826, also known as pyrilutamide, is a topical androgen receptor (AR) antagonist developed by Kintor Pharmaceutical (HKEX: 9939). It is designed to block androgen-mediated signaling directly at the hair follicle by competing with androgens like DHT for binding to the androgen receptor in local tissue.
Unlike oral finasteride or dutasteride, which reduce systemic DHT levels, pyrilutamide is designed to work locally at the scalp. It has very low transdermal absorption and its metabolites are low-activity compounds, which in theory may reduce the risk of systemic adverse effects relative to oral anti-androgens. However, longer and broader datasets will be needed to confirm this.
In preclinical binding affinity data, pyrilutamide appears to be the most potent of the topical AR antagonists currently in development. One way to measure this is IC50, which is the concentration of drug needed to block 50% of the target's activity. A lower IC50 means the drug is more potent. Pyrilutamide has an IC50 of 0.28 nM, compared to roughly 50 nM for clascoterone (Breezula/Winlevi) and roughly 40 uM for fluridil. In practical terms, pyrilutamide is roughly 180 times more potent by this measure. RU58841 is also used in the community but has less formal data. These comparisons come from different assay systems and should be interpreted with some caution, but the difference in potency is large.
On March 18, 2026, Kintor announced that the Phase 3 stage of its pivotal clinical trial for KX-826 tincture 1.0% reached its primary endpoint with statistically significant and clinically meaningful outcomes. These are top-line, company-reported results; full data has not yet been published or peer-reviewed.
The trial was a multi-center, randomized, double-blind, vehicle-controlled Phase II/III study with an adaptive design conducted at 26 clinical research centers in China. It enrolled 666 male patients with androgenetic alopecia and ran for 24 weeks of treatment plus a 14-day safety observation period.
The primary endpoint was change in target area non-vellus hair count (TAHC) from baseline:
1.0% BID (twice daily): +15.33 hairs/cm² from baseline, which was +10.65 hairs/cm² over placebo (p<0.0001).
0.5% BID (twice daily): +14.46 hairs/cm² from baseline, which was +9.78 hairs/cm² over placebo (p<0.0001).
Placebo: +4.68 hairs/cm² from baseline.
Top-line data suggest a favorable safety profile: no drug-related serious adverse events were reported, and there were no clinically significant differences in adverse event rates between the treatment groups and placebo.
The placebo-adjusted gain of +10.65 hairs/cm² at 24 weeks is directionally encouraging and looks competitive with established therapies. However, cross-trial comparisons should be made cautiously: populations, endpoints, baseline severity, counting methods, and timepoints differ across studies. The result is a meaningful signal for a topical treatment, but we should wait for head-to-head data before drawing firm conclusions about relative efficacy.
The most relevant comparison is Cosmo Pharmaceuticals' clascoterone (marketed as Breezula), another topical AR antagonist. Cosmo reported positive Phase 3 topline data in December 2025 and said it was preparing for parallel U.S. and European submissions following completion of the full safety dataset. Both drugs target the same receptor, but pyrilutamide has significantly higher binding affinity in preclinical data.
Kintor explicitly referenced this in their press release, positioning KX-826 as a potential competitor to Breezula and stating their goal is to be the first-in-class drug approved globally for topical AR antagonist treatment of AGA.
This is one of the biggest asterisks on the KX-826 data. The Phase 3 trial enrolled 666 patients across 26 centers, all in China, with an all-Chinese patient population. The NDA filing is planned with Chinese drug regulatory authorities, with no mention of US or EU filing in the press release.
China-only data may not be enough on its own for broad Western regulatory confidence or clinician uptake, especially for a product expected to compete globally. Genetic background, hair characteristics, and regulatory standards differ across populations. This does not invalidate the Chinese data, but it does mean that pyrilutamide is likely still years away from being available outside of China through regulatory channels.
Kintor has a credibility problem. The company has been accused of presenting misleading clinical data, and multiple researchers in the hair loss community have flagged concerns about how Kintor interprets and markets its study results. The company has been largely unresponsive to engagement from independent researchers. These are community-level accusations, not regulatory findings, but they are widespread and consistent.
Kintor has also been selling a cosmetic version of KX-826 on Amazon, which has caused significant confusion. The cosmetic version lists 0.5% pyrilutamide, which is close to the concentration that performed well in the Phase 3 trial (the 0.5% BID arm showed +9.78 hairs/cm² over placebo, nearly matching the 1.0% arm). On paper, that might suggest the Amazon product should work similarly. But the clinical formulation was developed as a drug with a specific vehicle chemistry designed for follicular penetration, manufactured under pharmaceutical-grade quality controls. The Amazon version is classified as a cosmetic, uses kopexil instead of minoxidil in its base, and is held to different manufacturing standards. Vehicle matters enormously for topicals: the same active ingredient at the same concentration in a different base can have dramatically different local bioavailability. Community reports of the Amazon cosmetic version have been consistently disappointing, which underscores this distinction.
Despite widespread skepticism toward Kintor as a company, the hair loss community is broadly positive on pyrilutamide as a molecule. The binding affinity data is strong: the IC50 of 0.28 nM is dramatically better than clascoterone and fluridil. The Ki (inhibition constant, a measure of how tightly a drug binds to its target receptor) is 24 nM in competitive binding assays, which also looks promising. However, DHT is a "stickier" ligand (its own Ki for the androgen receptor is in the low single-digit nanomolar range), which means you need high local concentrations of the drug to actually outcompete DHT for receptor binding.
Anecdotally, some long-term self-experimenters report favorable tolerability and efficacy with pyrilutamide. One experienced user described it as the only AR receptor antagonist that gave no side effects while providing the best efficacy. Real-world protocols in the community typically combine pyrilutamide with topical or low-dose oral dutasteride as a complementary approach. These reports are not a substitute for controlled long-term trial data, but they do provide useful signal about real-world tolerability.
One concern that has been raised: potential efficacy degradation over time. Some users have reported a plateau in results around 6 months, which may be specific to pyrilutamide rather than a general AR antagonist issue. Longer-term data from controlled trials would help clarify this.
Kintor is also developing GT20029, a PROTAC-based androgen receptor degrader. Unlike pyrilutamide, which blocks the AR, GT20029 aims to remove the receptor entirely. The PROTAC mechanism is conceptually interesting, but Phase 2 data was underwhelming: it showed no clear dose-response relationship and only modest separation from placebo. Main theories for the underperformance include pharmacokinetic challenges and the molecule being too large to penetrate effectively.
Very low systemic exposure (cmax <0.003 ng/mL) is seen as a potential safety advantage, and one community member noted that GT20029 could theoretically allow use of exogenous androgens (like TRT) without hair loss, since the AR would not exist in follicles to be activated. Community timeline estimates for GT20029 are optimistic at around 4 years, but given the underwhelming Phase 2 data, many remain skeptical.
Kintor has stated they plan to communicate with Chinese drug regulatory authorities and initiate the NDA submission for KX-826 1.0% in the near term. If approved in China, it could be available there within 1 to 2 years.
For the US and EU, the timeline is much longer. There is no announced US Phase 3 trial yet. Even if one were to start in 2026, it would take 2 to 3 years to complete, followed by another 12 to 18 months for FDA review. A realistic estimate for US availability would be 2030 at the earliest, assuming everything goes smoothly.
Our take: if pyrilutamide works as the Phase 3 data suggests, the realistic expectation is moderate regrowth and meaningful stabilization, not a full reversal of advanced hair loss. The trial showed roughly 10-15 new non-vellus hairs per cm² over 24 weeks, which is a solid result but not transformative on its own.
Where pyrilutamide gets more interesting is as part of a combination protocol. Because it works by blocking androgens at the receptor rather than reducing DHT systemically or stimulating growth directly, it pairs naturally with treatments that work through different mechanisms: minoxidil (potassium channel opening), microneedling (wound-healing response), low-dose oral or topical dutasteride (DHT reduction), topical T3 (thyroid-mediated metabolism), and latanoprost (prostaglandin pathway).
If pyrilutamide eventually reaches Western markets, its real value will likely be as the anti-androgen layer in a broader protocol rather than as a standalone treatment. That combination potential is what makes this molecule worth watching.
We will be watching closely for any US Phase 3 trial announcements. If pyrilutamide can replicate these results in a Western patient population with FDA-grade oversight, it would be a significant addition to the hair loss treatment landscape.
It is too early to say. The Phase 3 placebo-adjusted hair count gains are in a broadly similar range to what finasteride achieves, but these are cross-trial comparisons with different populations, endpoints, and timepoints. No head-to-head trial has been conducted. The potential advantage of pyrilutamide is that it works topically at the receptor rather than reducing systemic DHT, which may mean fewer systemic side effects, but this has not been proven in long-term comparative studies.
In the Phase 3 trial, top-line data reported no drug-related serious adverse events and no clinically significant difference in adverse event rates between pyrilutamide and placebo. However, these are company-reported top-line results from a 24-week trial. Longer-term safety data across larger and more diverse populations will be important before drawing firm conclusions about the full side effect profile.
There is no announced US Phase 3 trial for pyrilutamide yet. Even if one were to begin in 2026, it would take 2 to 3 years to complete, plus 12 to 18 months for FDA review. A realistic estimate for US availability is 2030 at the earliest. Kintor is currently pursuing NDA filing in China only.
No. Kintor sells a cosmetic product containing 0.5% pyrilutamide on Amazon, but it is not the same as the clinical-grade formulation used in the Phase 3 trial. The Amazon version uses a different vehicle (kopexil instead of minoxidil), is manufactured under cosmetic rather than pharmaceutical standards, and has produced consistently disappointing results according to community reports. The vehicle chemistry matters enormously for topical drug delivery, so the same active ingredient in a different base can perform very differently.
Both are topical androgen receptor antagonists, but pyrilutamide has significantly higher binding affinity in preclinical data (IC50 of 0.28 nM vs roughly 50 nM for clascoterone). Cosmo Pharmaceuticals reported positive Phase 3 data for clascoterone in December 2025 and is preparing for US and EU regulatory submissions. Pyrilutamide does not yet have Western regulatory filings. A direct clinical comparison has not been conducted.
Kintor Pharmaceutical Limited. "Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint." Press release, March 18, 2026.
Cosmo Pharmaceuticals. Breezula (clascoterone) Phase 3 results announcement. December 2025.
ClinicalTrials.gov. Kintor Pharmaceutical KX-826 clinical trial listings.
Kintor Pharmaceutical Limited. Official press release. Kintor Pharma
